Isabelle Liebschtz - Crossject Chief Board
| ALCJ Stock | EUR 2.06 0.04 1.98% |
Insider
Isabelle Liebschtz is Chief Board of Crossject
| Phone | 33 3 80 54 98 50 |
| Web | https://www.crossject.com |
Crossject Management Efficiency
The company has return on total asset (ROA) of (0.2773) % which means that it has lost $0.2773 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (8.3153) %, meaning that it generated substantial loss on money invested by shareholders. Crossject's management efficiency ratios could be used to measure how well Crossject manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| FFPM MBA | Biophytis SA | 52 | |
| Pascale MD | Poxel SA | N/A | |
| Brandon Owens | Nanobiotix SA | N/A | |
| Noah MBA | Poxel SA | 61 | |
| Bart Rhijn | Nanobiotix SA | N/A | |
| MBA PharmD | Poxel SA | N/A | |
| Sylvie Bertrand | Poxel SA | N/A | |
| Sarah Gaubert | Nanobiotix SA | N/A | |
| Earl Bergey | Nanobiotix SA | 68 | |
| Elsa Borghi | Nanobiotix SA | N/A | |
| Quentin Durand | Poxel SA | N/A | |
| Sophie HallakouBozec | Poxel SA | N/A | |
| Thomas Lamy | Biosynex | N/A | |
| Laurent Levy | Nanobiotix SA | 50 | |
| AnneJuliette MA | Nanobiotix SA | 49 | |
| David MD | Poxel SA | N/A | |
| Elizabeth MBA | Poxel SA | N/A | |
| Pr Prasad | Nanobiotix SA | 78 | |
| Benoit Canolle | Biophytis SA | 45 | |
| Kathryn McNeil | Nanobiotix SA | 48 | |
| Bolze PharmD | Poxel SA | N/A | |
Management Performance
| Return On Equity | -8.32 | |||
| Return On Asset | -0.28 |
Crossject Leadership Team
Elected by the shareholders, the Crossject's board of directors comprises two types of representatives: Crossject inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Crossject. The board's role is to monitor Crossject's management team and ensure that shareholders' interests are well served. Crossject's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Crossject's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Isabelle Liebschtz, Chief Board | ||
| Olivier Gir, COO Board | ||
| Henri Parseval, Member of the Management Board | ||
| Patrick Alexandre, Chairman of the Management Board and Co-Founder |
Crossject Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Crossject a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.32 | |||
| Return On Asset | -0.28 | |||
| Profit Margin | (1.74) % | |||
| Operating Margin | (1.95) % | |||
| Current Valuation | 123.81 M | |||
| Shares Outstanding | 34.9 M | |||
| Shares Owned By Insiders | 23.98 % | |||
| Shares Owned By Institutions | 1.72 % | |||
| Price To Earning | (4.61) X | |||
| Price To Book | 37.19 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Crossject Stock
Crossject financial ratios help investors to determine whether Crossject Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Crossject with respect to the benefits of owning Crossject security.